CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Incyte Corporation
Center for International Blood and Marrow Transplant Research
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Florida
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
The Royal Wolverhampton Hospitals NHS Trust
Beijing Biotech
Calibr, a division of Scripps Research
Alliance for Clinical Trials in Oncology
University of Arizona
Masonic Cancer Center, University of Minnesota
Ohio State University Comprehensive Cancer Center
Pfizer
University of Chicago
AbbVie
Thomas Jefferson University
Sellas Life Sciences Group
AvenCell Therapeutics, Inc.
Caribou Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Baylor College of Medicine
Tempus AI
Cancer Research UK
Gamida Cell ltd
National Institutes of Health Clinical Center (CC)
University of Miami
Ascentage Pharma Group Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Hospital Medical Center, Cincinnati
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
City of Hope Medical Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Prelude Therapeutics
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital